AstraZeneca’s Truqap in Combination with Faslodex Receives EC’s Approval for Treating Breast Cancer
Shots:
- The approval was based on the P-III (CAPItello-291) study assessing Truqap + Faslodex vs PBO + Faslodex to treat ER+, HER2‑ locally advanced or metastatic breast cancer patients (n=708) having one or more PIK3CA, AKT1 or PTEN-alterations post recurrence or progression on or after an endocrine-based regimen. Further applications are under review across China & other regions
- The results depicted reduction in the disease progression & death risk by 50% in patients having PI3K, AKT or PTEN alterations with mPFS of 7.3mos. vs 3.1mos. Data was published in The New England Journal of Medicine
- In addition, Astex Therapeutics will get milestone and royalties on first commercial sale across the EU as per an agreement b/w Astex & AstraZeneca
Ref: AstraZeneca | Image: AstraZeneca
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
